Sign in →

Test Code OPATM Opiate Confirmation, Meconium

Reporting Name

Opiate Confirmation, M

Useful For

Detection of maternal prenatal opiate/opioid use up to 5 months before birth

Performing Laboratory

Mayo Medical Laboratories in Rochester

Specimen Type

Meconium


Advisory Information


For chain-of-custody testing, order OPTMX / Opiate Confirmation, Chain of Custody, Meconium.



Specimen Required


Supplies: Stool container. Small (Random), 4 oz (T288)

Container/Tube: Stool container (T288)

Specimen Volume: 1 g (approximately 1 teaspoon)

Collection Instructions: Collect entire random meconium specimen.


Specimen Minimum Volume

0.3 g (approximately 1/4 teaspoon)

Specimen Stability Information

Specimen Type Temperature Time
Meconium Frozen (preferred) 28 days
  Refrigerated  28 days
  Ambient  14 days

Reference Values

Negative

Positives are reported with a quantitative LC-MS/MS result.

Cutoff concentrations

Codeine by LC-MS/MS: 50 ng/g

Hydrocodone by LC-MS/MS: 50 ng/g

Hydromorphone by LC-MS/MS: 50 ng/g

Morphine by LC-MS/MS: 50 ng/g

Oxycodone by LC-MS/MS: 50 ng/g

Oxymorphone by LC-MS/MS: 50 ng/g

Day(s) and Time(s) Performed

Monday through Friday, Sunday; Varies

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information

80361

80365

G0480 (if appropriate)

LOINC Code Information

Test ID Test Order Name Order LOINC Value
OPATM Opiate Confirmation, M 69026-3

 

Result ID Test Result Name Result LOINC Value
31848 Morphine 69027-1
31850 Oxymorphone 69028-9
31849 Hydromorphone 68541-2
31847 Codeine 68542-0
31852 Oxycodone 68543-8
31851 Hydrocodone 68544-6
31868 Interpretation 69050-3
31869 Chain of Custody 77202-0

Clinical Information

Opiates are naturally occurring alkaloids that are derived from the opium poppy and demonstrate analgesic effects. Opioids are derived from natural and semisynthetic alkaloids of opium or synthetic compounds(1):

-Codeine is a naturally occurring opioid agonist often incorporated into formulations along with acetaminophen or aspirin to increase its analgesic effect.(2) Codeine is metabolized to morphine and subsequently undergoes glucuronidation and sulfation.

-Morphine is an opioid receptor agonist that is used for major pain analgesia.(2) It has been shown to distribute widely into many fetal tissues,(4) and has been detected in meconium.

-Hydrocodone is a semisynthetic analgesic derived from codeine. Hydrocodone is 6 times more potent than codeine and is prescribed for treatment of moderate-to-moderately severe pain.(2) Hydrocodone undergoes O-demethylation in vivo, forming hydromorphone.

-Hydromorphone, a semisynthetic derivative of morphine, is an opioid analgesic. It is 7 to 10 times more potent than morphine, its addiction liability is similar to morphine.(2)

-Oxycodone, a semisynthetic narcotic derived from thebaine. It is metabolized by O-demethylation, forming oxymorphone.(2)

-Oxymorphone is a semisynthetic opioid derivative of thebaine and is indicated for moderate-to-severe pain.(2)

-Heroin, a semisynthetic derivative of morphine, is rapidly deacetylated in vivo to the active metabolite 6-monoacetlymorphine (6-MAM), which is further hydrolyzed to morphine.(2)

 

Opiates have been shown to readily cross the placenta and distribute widely into many fetal tissues. Opiate use by the mother during pregnancy increases the risk of prematurity and small size for gestational age. Furthermore, heroin-exposed infants exhibit an early onset of withdrawal symptoms compared to methadone-exposed infants. These infants demonstrate a variety of symptoms including irritability, hypertonia, wakefulness, diarrhea, yawning, sneezing, increased hiccups, jitteriness, excessive sucking, and seizures. Long-term intrauterine drug exposure may lead to abnormal neurocognitive and behavioral development as well as an increased risk of sudden infant death syndrome.

 

The disposition of opiates and opioids in meconium, the first fecal material passed by the neonate, is not well understood. The proposed mechanism is that the fetus excretes drug into bile and amniotic fluid. Drug accumulates in meconium either by direct deposition from bile or through swallowing of amniotic fluid. The first evidence of meconium in the fetal intestine appears at approximately the tenth to twelfth week of gestation, and slowly moves into the colon by the sixteenth week of gestation. Therefore, the presence of drugs in meconium has been proposed to be indicative of in utero drug exposure during the final 4 to 5 months of pregnancy, a longer historical measure than is possible by urinalysis.

Analytic Time

2 days

NY State Approved

Yes

Method Name

Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)